Raymond James Financial’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
Raymond James Financial's CCCC Position: Q3 2026 in Review
Raymond James Financial sold out of C4 Therapeutics (CCCC) in Q3 2026, closing a stake of 11,860 shares — an estimated $55.4K sold.
Raymond James Financial first reported a position in CCCC in Q2 2025 and held it in 2 quarters. The position peaked at $55.4K in Q2 2026. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Raymond James Financial reported no remaining C4 Therapeutics position as of Q3 2026 after selling out during the quarter.
- Raymond James Financial sold 11,860 C4 Therapeutics shares in Q3 2026, an estimated $55.4K.
- Raymond James Financial first reported a position in C4 Therapeutics in Q2 2025 and held it in 2 quarters.
- Raymond James Financial's C4 Therapeutics position peaked at $55.4K in Q2 2026.
- 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.